Overview

Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
0
Participant gender:
All
Summary
Diabetic macular edema (DME) is a sign of diabetic retinopathy that affects central vision. It is also a leading cause of visual decline in younger patients, especially in developing countries like our Arab community. Intra-vitrreal injection of anti-vascular endothelial growth factor (AVEGF) in management of DME had significant improvement in the final logMAR Un-corrected Distant Visual Acuity ( UCDVA) and logMAR Best Corrected Distant Visual Acuity (BCDVA), as well as reduction in the central retinal thickness from baseline measurement.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Minia University
Treatments:
Aflibercept
Ranibizumab
Criteria
Inclusion Criteria:

- Patients with type 1 or 2 diabetes mellitus with central DME clinically as well as
documented by optical coherence tomography (OCT) imaging

- The age of the patients at least 20 years old

- Patients not receiving AVEGF injection, at least for one year

- The BCDVA letter score of at least one eye (range, 0 to 115, with higher scores
indicating better visual acuity of 90 (Snellen = 20/32) to 40 (Snellen = 20/320) and
central DME .

Exclusion Criteria:

- Patients with cataract

- Glaucoma patient

- Previous AVEGF injection in less than one year

- Patients not attending all of the scheduled follow up visits